Écrit par GlobalData | 05 Mars 2018

Analysis of chronic kidney disease (CKD) revealed that the UK has the highest rate of diagnosis for early stage CKD out of the five major European markets (5EU*), according to GlobalData, a leading data and analytics company.

IMAGE FOR PUBLICATION, PLEASE CLICK HERE: ‘Total and diagnosed prevalent cases of CKD stages I–III, both sexes, ages 20 and over, 2016’

CKD, also known as...

Écrit par VALBIOTIS | 28 Février 2018

Le candidat VAL-070 vise à réduire les anomalies du bilan lipidique, ou dyslipidémies, facteurs de risque de maladies cardiovasculaires



40 volontaires présentant une élévation légère à modérée des taux de LDL cholestérol
et de triglycérides ont été inclus Des résultats cliniques de sécurité et d'efficacité attendus pour la mi-2018,

conformément au plan de marche...

Écrit par GlobalData | 28 Février 2018

Major growth in the anticoagulant market continued through 2017, primarily due to the increasing global prevalence of multiple cardiovascular (CV) indications including atrial fibrillation, acute coronary syndrome, peripheral artery disease, and venous thromboembolism. Yet, cheap and established anticoagulants such as warfarin and heparins continue to present a barrier for new...

Écrit par GlobalData | 28 Février 2018

In a bid to rid the world of infectious diseases, pharmaceutical companies are continuously striving to align their financial considerations – specifically, maximizing their return on R&D investment (ROI) – with corporate social responsibility. Drug and vaccine developers can reach this compromise by partnering with public authorities and other entities in order to mitigate upfront...